Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 (GPN00833), conducted in Chinese cataract surgery patients by licensee, Grand Pharma (0512.HK).APP13007 is a novel ophthalmic nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), and was recently approved and launched … [Read more...] about Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007
News
FDA grants fast track status to FELIQS’ FLQ-101 for ROP
The US Food and Drug Administration (FDA) has granted the lead asset for FELIQS, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). According to a press release1 from the company, FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.The candidate, FLQ-101, is a … [Read more...] about FDA grants fast track status to FELIQS’ FLQ-101 for ROP
VIDEO: Specialist shares positive experience with Eylea HD
November 06, 2024 3 min watch BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Michael W. Stewart, MD, shares his experience with Eylea HD in neovascular age-related macular degeneration and diabetic macular edema. Stewart was an early adopter of Eylea HD (aflibercept 8 mg, Regeneron) and initially used the drug on patients who were … [Read more...] about VIDEO: Specialist shares positive experience with Eylea HD
LumiThera’s Valeda Light Delivery System receives marketing authorization from FDA
LumiThera Inc. announced the US Food & Drug Administration (FDA) has authorized marketing of Valeda Light Delivery System for the treatment of patients with dry age-related macular degeneration (AMD).According to the company, the Valeda Light Delivery System is the first-ever authorized treatment by the FDA for vision loss in dry AMD patients and provides an improvement in … [Read more...] about LumiThera’s Valeda Light Delivery System receives marketing authorization from FDA
Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery
Aromatherapy may be a useful addition to help patients who are undergoing oculoplastic procedures under monitored anesthetic sedation. In this study, the use of aromatherapy resulted in lower postoperative anxiety and pain scores,1 according to patient reporting.First author Michael Chang, MD, from the Department of Ophthalmology and Visual Sciences, West Virginia University … [Read more...] about Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery
VIDEO: Verana Health introduces two novel data collection modules
November 06, 2024 5 min watch CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Sujay Jadhav, CEO of Verana Health, discusses two of the company’s new data collection modules which launched during the AAO meeting. The first is the Qdata Explorer, which allows ophthalmologists to explore and customize Verana’s existing data … [Read more...] about VIDEO: Verana Health introduces two novel data collection modules
Phase 3 LUGANO Trial explores EYP-1901’s potential to reduce treatment burden in wet AMD Patients
Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s non-inferiority objectives, treatment schedule, patient outcomes like reduced treatment burden, and anatomical stability. Patient interest is high, particularly among those wanting fewer injections, though recruiting treatment-naive … [Read more...] about Phase 3 LUGANO Trial explores EYP-1901’s potential to reduce treatment burden in wet AMD Patients
Evaluation of retinal and choroidal microvascular alteration after ICL V4c implantation based on OCTA
To evaluate the changes of retinal and choroidal microvascular including the superficial retinal capillary plexus (SCP), deep retinal capillary plexus (DCP), choriocapillaris (CC), and central retinal thicknes... … [Read more...] about Evaluation of retinal and choroidal microvascular alteration after ICL V4c implantation based on OCTA
FDA grants de novo authorization to photobiomodulation device for dry AMD
November 05, 2024 1 min read Key takeaways: The light delivery system maintained vision in a trial among patients with dry age-related macular degeneration. It is the first authorized treatment for vision loss related to dry AMD, according to a release. The FDA granted de novo marketing authorization Valeda Light Delivery System for the treatment of dry age-related … [Read more...] about FDA grants de novo authorization to photobiomodulation device for dry AMD
FDA clears investigational new drug application for wet AMD gene therapy
November 05, 2024 1 min read The FDA granted investigational drug clearance to HG202, a CRISPR/Cas13Y RNA-editing therapy for neovascular age-related macular degeneration, according to a press release from HuidaGene. According to the release, HG202 is the first CRISPR/Cas13Y RNA-targeting therapy in clinical development as well as the only clinical-stage CRISPR … [Read more...] about FDA clears investigational new drug application for wet AMD gene therapy